序贯不同B细胞抗原靶向CAR-T细胞治疗儿童复发/难治性伯基特淋巴瘤
该临床试验评估序贯不同B细胞抗原靶向CAR-T细胞治疗儿童复发/难治性伯基特淋巴瘤的可行性。23例患者接受首次CD19 CAR-T输注,未达持续完全缓解者按病情和CAR-T持久性序贯接受CD22及CD20 CAR-T输注。估计18个月完全缓解率为78%(95%CI 54%-91%),无进展生存率为78%(95%CI 55%-90%),安全性可控。
要点
- 序贯CD19、CD22、CD20 CAR-T可能使儿童复发/难治性伯基特淋巴瘤获得持久缓解。
- 首次CD19 CAR-T输注时≥3级细胞因子释放综合征发生率为34.8%,神经毒性为21.7%。
- 后续输注中>2级细胞因子释放综合征和神经毒性仅少数发生,所有不良事件均可逆。
核心结论
- 序贯不同B细胞抗原靶向CAR-T细胞治疗可能使儿童复发/难治性伯基特淋巴瘤获得持久缓解且安全性可控。
- 合并中枢神经系统受累的患者可能从序贯CAR-T细胞治疗中获益。
研究设计与样本
- 该临床试验纳入23例儿童复发/难治性伯基特淋巴瘤患者,首次接受CD19 CAR-T细胞输注。
- 未达持续完全缓解者根据疾病状态和每次输注后CAR-T细胞持久性,序贯接受靶向CD22继以CD20的1次或多次CAR-T细胞输注。
- 末次输注至截止日期中位时间为17个月(范围15-23个月)。
主要发现
- 估计18个月完全缓解率为78%(95%CI 54%-91%)。
- 估计18个月无进展生存率为78%(95%CI 55%-90%),其中 bulky disease 患者为78%(95%CI 37%-94%),中枢神经系统受累患者为60%(95%CI 25%-83%)。
- 首次CD19 CAR-T输注期间,所有患者中≥3级细胞因子释放综合征发生率为34.8%,神经毒性发生率为21.7%。
- 后续输注期间仅少数发生>2级细胞因子释放综合征和神经毒性,所有不良事件均可逆。
- 中枢神经系统受累与未受累患者间神经毒性严重程度无显著差异。
临床怎么用
- 对儿童复发/难治性伯基特淋巴瘤,可考虑序贯不同B细胞抗原靶向CAR-T细胞治疗策略。
- 中枢神经系统受累患者仍可能从序贯CAR-T细胞治疗中获益。
- 首次CD19 CAR-T输注需重点监测≥3级细胞因子释放综合征和神经毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Single antigen-targeted chimeric antigen receptor (CAR) T-cell therapy may be insufficient to induce a durable response in pediatric aggressive B-cell lymphomas. This clinical trial examined the feasibility of sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric relapsed/refractory (R/R) Burkitt lymphoma. Twenty-three patients received the first CD19 CAR T-cell infusion. The patients who did not achieve an ongoing complete response (CR) underwent 1 or more sequential infusions of CAR T-cell therapy that targeted CD22 followed by CD20 according to their disease status and CAR T-cell persistence after each infusion. The median time from the last infusion to the cutoff date was 17 months (range, 15-23 months). The estimated 18-month CR rate was 78% (95% confidence interval [CI], 54%-91%). The estimated 18-month progression-free survival rate was 78% (95% CI, 55%-90%), with 78% (95% CI, 37%-94%) in patients with bulky disease and 60% (95% CI, 25%-83%) in patients with central nervous system (CNS) involvement. During the first CD19 CAR T-cell infusion, grade ≥3 cytokine release syndrome (CRS) occurred in 34.8% and neurotoxicity occurred in 21.7% of all patients. During subsequent infusions, there were only a few incidences of grade >2 CRS and neurotoxicity. All adverse events were reversible. The severity of neurotoxicity was not significantly different between patients with CNS involvement and those who did not have CNS involvement. Sequential CAR T-cell therapy may result in a durable response and is safe in pediatric R/R Burkitt lymphoma. Patients with CNS involvement may benefit from sequential CAR T-cell therapy. This trial was registered at www.chictr.org.cn/index.aspx as #ChiCTR1800014457.
引用
- Liu Y, Deng B, Hu B, et al. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma. Blood Adv. 2022. PMID: 34521107. doi:10.1182/bloodadvances.2021004557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。